ReviewHealth science reports2025
Prognostic Indicators of Carbapenem-Resistant
Review in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Indicators of Carbapenem-ResistantHealth science reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Aims: To identify prognostic indicators of CRAB infections through a systematic review and meta-analysis. Methods: A systematic search was performed on PubMed, Embase, and Cochrane Library up to November 2024. Studies that reported the CRAB infections and their adverse outcomes (e.g., mortality, acute kidney injury, recurrent infections) were eligible for enrollment. Data were extracted from the studies by two reviewers, and the quality of the studies was determined using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using random-effects or fixed-effects models while considering the heterogeneity determined using the Results: Fourteen studies comprising 2250 patients were enrolled in the study. Notably, cardiovascular disease (OR: 1.59, 95% CI: 1.17-2.17), acute kidney injury (OR: 3.15, 95% CI: 1.69-5.88), shock (OR: 2.33, 95% CI: 1.50-3.63), pneumonia (OR: 1.28, 95% CI: 1.02-1.60), hematologic malignancy (OR: 2.23, 95% CI: 1.55-3.21), neutropenia (OR: 2.74, 95% CI: 1.48-5.06), and thrombocytopenia (OR: 1.49, 95% CI: 1.10-2.02) were found to be significant prognostic indicators predicting poor outcomes. The use of steroid therapy (OR: 1.29, 95% CI: 1.01-1.64) was linked to increased mortality risk. Conclusion: In this meta-analysis, we detected several prognostic indicators that correlated with poor adverse outcomes in patients with CRAB infections, which may help clinical decision-making and risk-stratification strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.